ICON: chronic rhinosinusitis by unknown
journal
Bachert et al. World Allergy Organization Journal 2014, 7:25
http://www.waojournal.org/content/7/1/25CONSENSUS DOCUMENT Open AccessICON: chronic rhinosinusitis
Claus Bachert1*†, Ruby Pawankar2†, Luo Zhang3, Chaweewan Bunnag4, Wytske J Fokkens5, Daniel L Hamilos6,
Orathai Jirapongsananuruk4, Robert Kern7, Eli O Meltzer8, Joaquim Mullol9, Robert Naclerio10, Renata Pilan11,
Chae-Seo Rhee12, Harumi Suzaki13, Richard Voegels14 and Michael Blaiss15Abstract
Chronic rhinosinusitis (CRS) is a public health problem that has a significant socio-economic impact. Moreover, the
complexity of this disease due to its heterogeneous nature based on the underlying pathophysiology - leading to
different disease variants - further complicates our understanding and directions for the most appropriate targeted
treatment strategies. Several International/national guidelines/position papers and/or consensus documents are
available that present the current knowledge and treatment strategies for CRS. Yet there are many challenges to
the management of CRS especially in the case of the more severe and refractory forms of disease. Therefore, the
International Collaboration in Asthma, Allergy and Immunology (iCAALL), a collaboration between EAACI, AAAAI,
ACAAI, and WAO, has decided to propose an International Consensus (ICON) on Chronic Rhinosinusitis. The purpose
of this ICON on CRS is to highlight the key common messages from the existing guidelines, the differences in
recommendations as well as the gaps in our current knowledge of CRS, thus providing a concise reference. In this
document we discuss the definition of the disease, its relevance, pharmacoeconomics, pathophysiology, phenotypes
and endotypes, genetics and risk factors, natural history and co-morbidities as well as clinical manifestations and
treatment options in both adults and children comprising pharmacotherapy, surgical interventions and more
recent biological approaches. Finally, we have also highlighted the unmet needs that wait to be addressed
through future research.
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Rhinosinusitis (RS) is a significant health problem which
seems to mirror the increasing frequency of allergic
rhinitis and which results in a large financial burden on
society. Rhinosinusitis is a broad umbrella term cover-
ing multiple disease entities, including acute RS (ARS),
CRS with nasal polyps (CRSwNP) and CRS without
nasal polyps (CRSsNP). In this document only Chronic
Rhinosinusitis with or without polyps will be discussed.
The last decade has seen the development of a number
of guidelines, consensus documents and position papers
on the epidemiology, diagnosis and treatment of RS [1-6].
All guidelines being published in recent years have
adopted the term r’hinosinusitis’ instead of sinusitis.* Correspondence: Claus.Bachert@ugent.be
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unless otherwise stated.Recent data have demonstrated that CRS affects ap-
proximately 5–15% of the general population [7-11].
The prevalence of doctor-diagnosed CRS was found to
be 2-4% [9].
Chronic Rhinosinusitis in adults is in most guidelines
defined as an inflammation of the nose and the paranasal
sinuses characterised by at least 8-12 weeks of at least 2
symptoms, like nasal blockage/obstruction/congestion,
nasal discharge (anterior/posterior nasal drip), facial
pain/pressure and/or reduction or loss of smell and either
endoscopic signs of disease or relevant CT scan changes.
Confirmation of sinus disease using an objective measure
is required because the symptoms can be nonspecific and
mimicked by several disease entities (eg, upper respiratory
tract infection, (allergic) rhinitis, migraine). Conversely, in
the absence of symptoms, diagnosis of CRS based on radi-
ology alone is not appropriate because of a high incidence
of radiological anomalies on CT scans in normal indi-
viduals. Thus, the presence of symptoms plus an objectivel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bachert et al. World Allergy Organization Journal 2014, 7:25 Page 2 of 28
http://www.waojournal.org/content/7/1/25finding are necessary [4]. Addition of nasal endoscopy to
symptom assessment substantially increased diagnostic ac-
curacy in confirming the presence of CRS using sinus CT
as the criterion standard [12]. CRS is usually further cate-
gorized based on the absence or presence of nasal polyps
(CRS without nasal polyps, CRSsNP; or CRS with nasal
polyps, CRSwNP). Although both are characterized by
mucopurulent drainage and nasal obstruction, CRSsNP is
frequently associated with facial pain/pressure/fullness
whereas CRSwNP is frequently characterized by hyposmia.
Nasal polyps (CRSwNP) are defined as bilateral pedun-
culated lesions as opposed to cobblestoned mucosa,
endoscopically visualised in middle meatus [5]. In some
guidelines further categorisation or subanalysis of pa-
tient groups with CRSwNP is advised e.g. into allergic
fungal rhinosinusitis [1], aspirin exacerbated respiratory
disease [1-4], and/or cystic fibrosis [1,5,6,13].
The definition in children is less well developed. In the
EPOS2012 guidelines, chronic rhinosinusitis in children
is defined as an inflammation of the nose and the parana-
sal sinuses characterised by at least 8-12 weeks of at least
symptoms of nasal blockage/obstruction/congestion and/
or nasal discharge (anterior/posterior nasal drip), com-
bined with facial pain/pressure and/or reduction of smell
or cough and either endoscopic signs of disease or rele-
vant CT scan changes.
The goal of CRS treatment is to achieve and maintain
clinical control and avoid complications. The terms con-
trol of disease and difficult-to-treat rhinosinusitis have
been defined. Control is defined as a disease state in which
the patients do not have symptoms or the symptoms are
not bothersome, if possible combined with a healthy or
almost healthy mucosa and only the need for localFigure 1 Prevalence of CRS. The GA2LEN study. Reported prevalence of Cmedication. Difficult-to-treat rhinosinusitis was defined as
persistent symptoms of rhinosinusitis despite appropriate
treatment (recommended medication and surgery). A
significant, although presently unknown, percentage of
patients with CRS continue to experience bothersome
symptoms despite adequate treatment. This group with
so-called severe chronic upper airway disease (SCUAD)
represents a therapeutic challenge [14].
Prevalence of chronic rhinosinusitis
Studies designed to investigate Chronic Rhinosinusitis
(CRS) epidemiology play an important role in assessing its
distribution, analyzing risk factors, and promoting public
health policies. Epidemiological data on rhinosinusitis are
scarce, and study methods and response rates vary widely.
As suggested by the European Position Paper on Rhino-
sinusitis and Nasal Polyps (EPOS 2007 and 2012), from an
epidemiological standpoint, chronic rhinosinusitis (with or
without nasal polyps) in adults is defined as: presence of
two or more symptoms one of which should be either
nasal blockage/obstruction/congestion or nasal discharge
(anterior/posterior nasal drip): ± facial pain/pressure; ±
reduction/loss of smell; and symptoms must be present
for more than 12 weeks [5,13]. In a recent multicenter
study performed as part of the Global Allergy and
Asthma European Network project (GA2LEN), a postal
questionnaire with the EPOS criteria was sent to a ran-
dom sample of adults aged 15-75 years in 19 centers of
12 countries in Europe. The GA2LEN study concluded
that the overall prevalence of CRS by EP3OS criteria
was 10.9% (range 6.9- 27.1) [9] (Figure 1) and that CRS
was associated with asthma, specifically late-onset
asthma [7].RS throughout Europe [9).
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veys carried out by the National Center for Health found
a prevalence of self-reported rhinosinusitis of 13% in
2009. The prevalence of CRS was defined as an affirma-
tive answer to the question “In the last 12 months, has
the patient had sinusitis diagnosed by a health profes-
sional? [16]). A recent study in Sao Paulo, a municipality
that has an urban population of 11 million, using a com-
plex two-stage cluster sampling plan, and personal inter-
views and defining CRS based on the EPOS criteria
found a prevalence of 5.51% [15]. The prevalence of
doctor-diagnosed using ICD-9 codes as an identifier of
CRS in Olmsted, Minnesota reports a prevalence of 2%
of the population [17]. In Canada, the prevalence of CRS,
defined as an affirmative answer to the question ‘Has the
patient had sinusitis diagnosed by a health professional
lasting for more than 6 months?’ ranged from 3.4% in
male to 5.7% in female subjects, with a response rate of
82% [18]. In a nationwide survey in Korea, the overall
prevalence of CRS, defined as the presence of nasal ob-
struction and nasal discharge lasting more than 3 months
together with the endoscopic objective findings such as
discolored nasal drainage in the nasal passage or nasal
polyps, was 6.95% [8].
Pharmacoeconomics of CRS
The overall expenditure for CRS has been recognized as
a socioeconomic burden, and it includes not only the cost
for the medical management of the disease (medication,
doctor’s visits, surgery), but also includes costs to the soci-
ety (medical care systems) and economy (absenteeism and
presenteeism, resulting in decreased work productivity).
The number of US office-based doctor visits resulting
from a diagnosis of chronic rhinosinusitis in 2000 was ap-
proximately 11.6 million [19]. Mean medical resource
costs were US$921 per patient-year. CRS caused an
average of 4.8 days of missed work per 12-month period.
The overall yearly economic cost of CRS was US $1539
per patient [20].
In the United States, the national health care costs of
CRS in 2007 were estimated as US $8.6 billion per year
due to increases in office-based and prescription expendi-
tures (this figure does not include over-the-counter medi-
cation or other expenditure by the patient [21]). It has
been estimated that antibiotics to treat CRS only may cost
more than US $150 million per year [20] and more than
257.000 patients undergo ambulatory sinus surgery per
year [22].
Genetics and epigenetics
Chronic rhinosinusitis (CRS) is a complex inflammatory
disease, in which both genetic and environmental factors
contribute to its pathogenesis [23]. Based on family
studies, it has been estimated that CRS exhibits aheritability of 13% to 53% [24-26], with highest heritabil-
ity seen in the asthma-nasal polyp-aspirin intolerance
triad [25]. Asthma, a disease with an even higher herit-
ability, has been reported to occur in 20% to 31.9% of
CRS subjects [27,28], further indicating the potential gen-
etic component in the etiology of CRS. In addition, the
consistent features between nasal polyps/CRSwNP and
cystic fibrosis (CF), a common genetic disorder caused by
mutations in the CFTR gene, provides extra evidence that
genetically determined alterations of sinus mucosal im-
munology contribute to the development of CRS [29-32].
However, data obtained from studies of CRS in twins are
inconsistent [33-35] and suggest that a combination of
genetic and environmental factors is likely to play a role
in the development of CRS.
Two techniques; namely the candidate gene approach
and the genome-wide association study (GWAS) have
commonly been employed to investigate population-
based associations between specific alleles and certain
common diseases. Candidate gene or pathway association
studies, which focus on single nucleotide polymorphisms
(SNPs) among unrelated individuals characterized by the
presence or absence of a phenotypic trait of interest, have
mostly been performed in the identification of genes im-
plicated in CRS [36]. These studies mainly exerted great
attention on the genes related to innate immunity, rele-
vant regulatory factors, or downstream products involved
in the pathogenesis of CRS. An earlier study by Molony
et al [37] investigated the association between several
human leukocyte antigen (HLA) alleles and CRS and
demonstrated that the incidence of HLA-A1B8 was sig-
nificantly increased in CRSwNP patients with concomi-
tant asthma and aspirin intolerance [37]. Similarly,
Luxenberger et al [38] performed a case-control study
and reported that HLA-A74 was associated with sus-
ceptibility to the development of CRSwNP. Likewise,
HLA-DQB1*03 was found to be a risk factor for allergic
fungal rhinosinusitis and hypertrophic sinus disease
[39]. Although several other HLA alleles, SNPs or hap-
lotypes have also been shown to be associated with CRS
in different ethnicity groups [40-45], these studies have
been limited by the complicated nature of the genotyp-
ing procedures and underpowered statistics.
Although the development of CRS has been reported to
be associated with a variety of cytokines (including IL1α
[46-48], TNFA [47-49], IL1B [47,50], IL10 [50,51], IL33
[52], TGFB1 [53], TNFA1P3 [54], IL4 [55], TSLP [56]),
cytokine receptors (IL1RN [57], IL22RA1 [58], IL1RL1 [59],
MET [60,61]), immunity pathways (SERPINA1 [62,63]
TLR2 [64]. IRAK4 [65], NOS1 [66], NOS1AP [66],
ALOX5AP [67], ALOX5 [67], CYSLTR1 [67], TP73 [68],
COX2 [61]) and airway remodelling related molecules
(CACNG6 [69], MMP9 [70,71], EMID2 [72]), up to now
only two polymorphisms in the IL1A (rs17561) and
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et al. [46] first reported rs17561 located in exon 5 of the
IL1A gene genotyped differently between asthmatics with
and without NP in the Finnish population [46]. Similarly,
another study demonstrated that IL1A (rs17561), IL1B
(rs16944) and TNFA (rs361525 and rs1800629) were asso-
ciated with susceptibility to CRSwNP in a Turkish cohort
[47]. Furthermore, an association between IL1A_rs17561
and the development of severe CRS was shown to be
present in a replication study involving 206 Caucasian
patients and 106 postal code-matched controls [48].
The SNP rs1800629 in the TNFA gene associated to
CRSwNP has also been replicated in two studies [48].
Compared with candidate gene association studies,
GWAS do not test any specific hypotheses, but examine
the entire human genome to discover any associations
between particular genes and disease. However, GWAS
of CRS are still lacking due to the high costs involved in
genotyping and the large patient cohorts required to en-
sure sufficient statistical power. One DNA pool-based
GWAS has nevertheless determined allele frequencies in
separate pools of high density SNP microarray-hybridized
DNA from Caucasian CRS patients and control subjects
[73]. In this study, the authors identified 600 SNPs from
445 genes with a P value < 0.05 among 210 CRS patients
and 189 controls; with the top 10 associated genes sug-
gesting a potential role for interactions at the level of the
basement membrane and extracellular matrix (LAMA2
and LAMB1), mitochondrial function (PARS2) and lipo-
polysaccharide degradation (AOAH). More recently,
Zhang and colleagues [74] replicated 17 of these CRS
susceptibility genes in a Han Chinese population, and
demonstrated that at the same SNP locus (rs4504543)
an AOAH gene was significantly associated with CRS;
thus indicating the potential common genetic basis in
the development of CRS in Chinese and Caucasian
populations.
Epigenetics is defined as the study of heritable changes
in gene expression or cellular phenotype caused by
mechanisms other than changes in the DNA sequence.
Epigenetic modifications/marks determine how the in-
formation in genes is expressed and used by cells, and
generally comprise DNA methylation, modification of
histone tails and noncoding RNA. Epigenetic mechanisms
regulate the expression of key molecules or pathways in
immunity and relate those to the pathogenesis of im-
munologic and inflammatory disorders. It has been
suggested that hypermethylation of CpG islands in
genes promotes gene silencing. One study investigating
the epigenetics of CRS has indicated that activated eo-
sinophils, which are found predominantly in CRSwNP
patients, may lead to DNA modifications and gene si-
lencing via 5BrC and aberrant methylation patterns
[75]. A recent study examining genome-wide DNAmethylation levels in CRSwNP tissues and peripheral
blood cells collected from aspirin-intolerant asthma
(AIA) and aspirin-tolerant asthma (ATA) patients [76]
showed that CRSwNP patients with AIA demonstrated
characteristic methylation patterns affecting 337 genes.
MicroRNAs are a class of small noncoding RNAs that
regulate the target gene expression through effects on
mRNA stability and translation. A significant change in
gene expression in sino-nasal mucosa from patients
with CRS [77] has suggested that CRS may be particu-
larly sensitive to microRNA (miR) regulation. A recent
study by Zhang et al [78] reported that there was overex-
pression of miR-125b in eosinophilic CRSwNP individuals
and that this miR played an important role as a regulator
of innate immunity via the miR-125b-EIF4E-binding pro-
tein 1 in the IFN pathway for mucosal eosinophilia in such
patients. Similarly, another study demonstrated that
PACT, a protein activator of the interferon-induced
protein kinase, associated with the microRNA machinery
may be involved in plasma cell function and eosinophilic
inflammation in CRSwNP [79,80].
Although genetic and epigenetic mechanisms contrib-
ute to our understanding of the cause and pathogenesis
of CRS, and additionally provide an insight into potential
future targets and corresponding interventions, CRS re-
mains a complex multifactorial disease, which requires
further differentiation. The challenge will be to understand
how genetic variation, epigenetic marks and environmen-
tal factors interact to lead to the development of specific
CRS endotypes.
Remodeling in CRS
Remodeling is a critical aspect of normal physiology and
wound repair in all organs, being defined as ‘modeling
again’ or ‘modeling differently’. It is a dynamic process
resulting in both extracellular matrix (ECM) production
and degradation. This may lead to a normal reconstruc-
tion processes with restoration of normal tissue, or may
result in pathological reconstruction with formation of
pathological tissue [81].
Remodeling in lower airway disease has been extensively
studied and reviewed. It includes changes in airway epithe-
lium, lamina propria and submucosa, resulting in airway
wall thickening. The main histological features of re-
modeling are macrophage and lymphocyte infiltration,
fibroblast proliferation, angiogenesis, increased connective
tissue formation (fibrosis) and tissue destruction. For the
upper airway, there is clear evidence that remodeling is
also present in chronic rhinosinusitis as well as allergic
rhinitis [81-83]. Based on the differential expression of
inflammatory cytokines and remodeling patterns, chronic
rhinosinusitis with polyp formation (CRSwNP) can be
distinguished from chronic rhinosinusitis without polyp
formation (CRSsNP).
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ance of CRSwNP, characterized by albumin accumulation
and edema formation, whereas CRSsNP is marked by
fibrosis [84]. CRSsNP is typically showing more neutro-
philic inflammation than CRSwNP, and also fibrosis
formation of the extracellular matrix consisting of ex-
cessive collagen deposition and thickening of collagen
fibers in the absence of pseudocysts. In contrast, the
histology of CRSwNP is typically characterized by the
presence of pseudocyst formations consisting of albumin
accumulation and edema formation, a lack of collagen
within the extracellular matrix and an excessive infiltration
of inflammatory cells mainly consisting of eosinophils in
about 80% of the Caucasian polyps.
Although Caucasian CRSwNP is characterized by a
predominant Th2-type eosinophilic inflammation with
high levels of IL-5, ECP and local IgE, and Asian CRSwNP
preferentially has a Th1/Th17 polarization signature, typ-
ical remodeling features in nasal polyps from both ethnic
groups are albumin accumulation and edema (pseudocyst)
formation within the extracellular matrix. This questions
the link between inflammation and remodeling, as do
findings of remodeling in early CRSsNP disease without
signs of inflammation [85].
One striking feature is the relative lack of the transform-
ing growth factor beta (TGF- f1) signaling in CRSwNP
and consecutively a lack of collagen production [86]. In
contrast, CRSsNP is characterized by a mainly Th1-driven
inflammation with active TGF-β1 signaling and subse-
quent excessive collagen deposition and fibrosis formation.
TGF-β plays a crucial role in remodeling processes in the
airway by the attraction and induction of proliferation of
fibroblasts, and the up-regulation of the ECM synthesis
[87]. Increases in TGF-β1 protein and mRNA have been
measured repeatedly in CRSsNP, in contrast to decreases
or lack of increases in CRSwNP [83,84].
Remodeling is a dynamic process in both health and dis-
ease, balancing ECM production and degradation. ECM
breakdown is regulated mainly by a family of matrix me-
talloproteinases (MMPs) and their inhibitors, tissue inhibi-
tors of metalloproteinases (TIMPs). In sinus disease,
differing results and a multitude of MMP subtypes make it
difficult to interpret data. In CRSsNP, levels of MMP-9
(gelatinase B) and its inhibitor, TIMP-1, are increased, and
might counteract each other. Findings of increased con-
centrations of MMP-9, but not of TIMP-1, in nasal polyps
suggest that the MMP-9/TIMP-1 imbalance is associated
with ECM degradation in CRSwNP [87]. In addition,
MMP-9 was found to be involved in wound healing, and
high levels predicts poor healing after sinus surgery [88].
Recent studies also found that the regulation of tissue-
plasminogen activators (u-PA and t-PA) might contribute
to tissue remodeling and pathogenesis of CRSwNP
[89,90]. However, findings are partially contradicting,which might be due to a lack of correct sub-classification
of the disease.
Anti-inflammatory medications (topical steroids being
the gold standard) have the potential to suppress inflam-
mation and edema formation. However, studies suggest
that anti-inflammatory approaches alone are not suc-
cessful in reversing changes such as collagen deposition,
indicating that early treatment might be crucial for pre-
venting disease progression. Antibiotics such as doxycyc-
line also possess an anti-MMP effect, and have been
shown to modify polyp size and healing after surgery
[91,92]. Future studies are needed to optimize the usage
of remodeling interventions in disease and after surgery.
The conservative philosophy of endoscopic sinus sur-
gery and minimally invasive sinus technique to relieve
ostial obstruction is very likely insufficient in handling
severe disease states with high inflammatory loads and/
or a dysfunctional mucosa. These patients derive more
benefit from maximal surgical options directed toward
eliminating the inflammatory load and improving access
for topical medication to retard or reverse the mucosal
damage. Additionally, removal of irreversibly diseased
mucosa allows healthy mucosa to regenerate in its place.
Due to the complexity of disease in recalcitrant sinusitis,
it is likely that multimodality treatment will serve these
patients best [93].
Epithelial barrier and innate immunity
The sinonasal mucosa serves as the site of interface with
inhaled irritants, aero-allergens, commensal organisms
and pathogens. Mucociliary clearance and apical junc-
tional complexes (AJCs) between epithelial cells comprise
a mechanical barrier between host and environment. Re-
spiratory mucus, which is produced by goblet cells and
submucosal glands, traps foreign material and moves it
out of the sinuses and nasal cavity towards the nasophar-
ynx. Genetic defects in mucociliary flow are associated
with a high incidence of CRS [94,95]; acquired mucociliary
defects and increased mucus viscosity have also been
suggested to underlie idiopathic CRS [96,97]. Sinonasal
epithelial cells (ECs), residing beneath the mucus layer,
are linked by tight and adherence junctions (AJCs), cre-
ating a relatively impermeable barrier. Proteins com-
prising the AJC are subject to degradation by proteases,
such as those found in allergens, bacteria and fungi. In
CRSwNP, significantly altered levels of adhesion com-
plex proteins have been identified [98-101] as well as
lower levels of intrinsic protective anti-protease activity
[102,103]. Functional studies have also recently suggested
that the epithelial barrier is more permeable in nasal
polyps [100,101]. Taken together, these studies suggest
that mucociliary dysfunction may play a role in the patho-
genesis of CRS broadly, while a porous barrier has been
more closely linked to CRSwNP.
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barrier may trigger an innate immune response. Sinonasal
epithelial cells (ECs) and other cell types present express
pattern recognition receptors (PRRs) that recognize patho-
gen associated molecular patterns (PAMPs) present on
microbes [104,105]. Cellular damage is detected through
damage-associated molecular patterns (DAMPs) [106,107]
and the combined signal of foreign material plus cellular
damage governs the release of host defense molecules,
cytokines and chemokines. Toll-like receptors (TLRs)
are the best-studied PRR, with potential derangements
contributing to the development of CRS, but data are
thus far inconclusive [105,108-111]. More recent evi-
dence has indicated that classical taste receptors are
also present on ECs functioning as PRRs by detecting
microbial products and triggering enhanced mucociliary
clearance and release of host defense molecules [112].
Genetic variation in these taste receptors may play a
role in CRS disease susceptibility [113].
Nasal ECs secrete a vast arsenal of host defense mole-
cules into the nasal mucus at baseline, with levels aug-
mented upon PRR stimulation [114-116]. These innate
responses in ECs are modulated in part by IL-22 and its
receptor IL-22R [117,118] which act in part through the
transcription factor STAT 3, broadly mediating mucosal
host defense and epithelial repair [119-122]. Decreased
expression of some host defense molecules has been as-
sociated with CRS [123-127]. While the mechanism for
this weakened host defense is unclear, diminished ex-
pression of IL-22R [128] and blunting of the STAT 3
pathway [129] have been reported in CRS. Regardless,
the presence of diminished host defense molecules in
CRS suggests the hypothesis that a primary sinonasal
innate immune defect may contribute to local microbial
proliferation fostering the development of CRS in a subset
of patients [130].
Beyond host defense molecules, ECs also secrete cy-
tokines and chemokines in response to PRR which fos-
ter an inflammatory response and attract and activate
innate effector cells [114,131-136]. In addition, cyto-
kine crosstalk between ECs, innate lymphoid cells
(ILCs) and dendritic cells matches the appropriate in-
nate and adaptive response to foreign stimuli. In health,
this maintains mucosal homeostasis with (a) tolerance
of allergens and commensals and (b) defense against
pathogens without the development of chronic inflam-
mation. CRSwNP is characterized by chronic and ex-
cessive Th2 inflammation and the specific EC cytokines
IL-25, IL-33 and TSLP have been implicated in disease
pathogenesis via effects on dendritic cells and type 2
ILCs [127-139]. In support of this hypothesis, large
numbers of Type 2 ILCs are present in nasal polyps
[140] and high levels of TSLP have been identified sug-
gesting a key role for this cytokine in polyppathogenesis [141-145]. Levels of other epithelial cyto-
kines with Th2 properties, such as IL-33, have been re-
ported as higher in recalcitrant CRSwNP [146] and
genetic studies also suggest that variation near the IL-
33 gene is associated with CRSwNP [52]. In regard to
IL-25, there is no current evidence for elevated expres-
sion or activity of this cytokine in CRS. EC chemokines
play a major role in the attraction and activation of in-
nate effector cells including eosinophils, mast cells,
neutrophils and macrophages. The tissue changes as-
sociated with CRS are presumably secondary to toxic
effects of excessive or persistent degranulation of these
cell types [6]. In regard to CRS pathogenesis, most
interest has centered on eosinophils [147] and mast
cells [148] but elevated levels of neutrophils and mac-
rophages are present and phagocytic activity may be
impaired in CRS [149].
ECs express enzymes involved in the generation of
reactive oxygen species (ROS) and reactive nitrogen
species (RNS) that are important in multiple epithelial
processes including mucin production, epithelial re-
pair, innate immunity and response to environmental
toxins [114,150]. Variations in activity of these enzyme
systems have been proposed to impair barrier function
and innate immunity in CRS [151-153] but the clinical
significance remains uncertain [154]. EC enzyme sys-
tems also likely contribute to tissue levels of eicosa-
noids, which have been implicated in subtypes of
CRSwNP [155-157].
Broadly speaking, CRS has been proposed as a disease
characterized by a dysfunctional host-environment inter-
action at the sinonasal mucosa [6]. While the association
of asthma and CRS is well established, the prevalence of
other chronic inflammatory disorders in the CRS popu-
lation was not found to be significantly above back-
ground [157]. These observations suggest that host
defects in CRS will be centered in the airway mucosa
giving rise to the ‘immune barrier hypothesis’ which
proposes that defects in the coordinated mechanical
barrier and/or the innate immune response of the sino-
nasal epithelium manifests as CRS [158]. Diminished in-
nate host defense coupled with a porous barrier should
theoretically lead to increased microbial colonization,
accentuated barrier damage and a compensatory adap-
tive immune response [130]. The ‘immune barrier hy-
pothesis’ does not specifically address the Th subset
skewing observed in many CRS subtypes, including the
Th2 pattern and B cell infiltrate observed in Western
CRSwNP patients. This implies additional, as yet un-
determined mechanisms, perhaps centered on EC and
ILC signaling, that foster an inappropriate local, adap-
tive response in the sinonasal mucosa. An excessive
and/or inappropriate Th2 adaptive response in this setting
may further compromise barrier function and diminish
Bachert et al. World Allergy Organization Journal 2014, 7:25 Page 7 of 28
http://www.waojournal.org/content/7/1/25innate immunity, thereby creating a self-perpetuating
cycle of disease.
Pathophysiology: acquired immunity, T cell
signatures
Tcell patterns, Tregs, follicular structures, immunoglobulins.
The acquired immune system consists of T cell and B
cell subsets, armed with different abilities to fight patho-
gens and orchestrate inflammation. CRSsNP and CRSwNP
are characterized by specific compositions of lymphocytes;
and specifically T helper cell signatures do have an im-
portant impact on the type of mucosal inflammation with
respect to neutrophilic vs. eosinophilic predominance.
Today, we recognize several Th cell signatures in CRS,
with Th1, Th2 and Th17 cells being most prominent
[159,160]. Pilot studies in upper airway mucosal tissue
pointed to the fact that interferon-gamma producing Th1
cells were characteristic for CRSsNP, whereas interleukin-
5 producing Th2 cells were typically found in CRSwNP
[159]. Studies together with Chinese colleagues revealed
later that the picture is much more complex, with Th1,
Th2 and Th17 cells coexisting in the airway mucosa, and
that the relative distribution of those cells would differ
greatly between continents [160]. In Caucasians, more
than 80% of polyps express a Th2 profile, whereas in
China, polyps express a predominant Th17 cell profile.
However, Caucasian nasal polyps in cystic fibrosis patients
do also mostly show a characteristic Th17 signature [161].
Recent studies showed that the signature of Th cells may
be different from one to the next individual, demanding a
much more specific investigation into clusters of T cells
orchestrating the inflammation in subgroups of patients,
which may be associated with very different co-morbidity
profiles [162] (see also chapter on cluster analysis). Fur-
thermore, Asian more than Caucasian polyps may not
show a dominant T cell at all, underlining the dissociation
between remodeling and inflammatory patterns in nasal
polyp disease [163].
Apart from T helper cells, the presence and functionality
of T regulatory cells differentiates CRSsNP and CRSwNP
in that a deficit of Tregs has been described in nasal
polyps, but not in CRSsNP [164,165]. An impaired migra-
tion of Treg cells and a deficit in TGF-beta formation has
been claimed to possibly cause this observation [164,166].
It is reasonable to appreciate that a deficit in Foxp3 ex-
pressing Tregs could account for the persistence of in-
flammation observed specifically in CRSwNP, although
this needs to be tested. Recent evidence has pointed to
suppressor of cytokine signaling3 (SOCS3) protein,
overexpressed in CRSwNP by dendritic cells and Tregs,
as a candidate for therapy, as SOCS3 suppresses the
expression of Foxp3 [167].
Recently, also IL-21 and IL-21-producing T follicular
helper (Tfh)-like cells were identified as an increasedpopulation in nasal polyposis, with the staphylococcal
superantigen SEB being one of the triggers for IL-21 ex-
pression [168]. The authors speculate that T-follicular
helper cells and their product, IL-21, are important in
the pathophysiology of nasal polyposis by stimulating
local immunoglobulin production and germinal center
formation.
Apart from an increase in T cells, also the numbers of
B and plasma cells are significantly up-regulated in
CRSwNP [159], suggesting a highly activated local im-
munoglobulin production. The overproduction of B cell-
activating factor of the TNF family BAFF and other plasma
cell differentiation molecules may partially account for this
up-regulation [134,169]. There is clear evidence for local
receptor revision and class switching in CRSwNP, but not
CRSsNP, and the expression of inducible lymphoid tissue,
follicle-like structures, has been demonstrated in the air-
way mucosa of polyps [169], as well as the expression of
all necessary regulators of class switch recombination in-
cluding AID, RAGs and others [169,170]. Specifically nasal
polyps thus should be understood as an immunoglobulin
generating disease, the role of which is not completely
understood so far.
Immunoglobulin synthesis
Although the etiology of the inflammation associated
with CRS is not completely understood, the presence of
bacteria within the nose and paranasal sinuses is well
documented [171,172]. Yet there is much diversity on
the type of pathogens identified primarily due to the
point in time, manner and mode of sample collection,
treatment methods used and techniques of bacterial cul-
ture. In CRS without underlying infection, bacterial
colonization is considered to exacerbate a noninfectious
inflammatory response via bacterial allergic mechanisms.
Bacteria- specific IgE has been reported in 57% of pa-
tients with CRS as compared to only 10% in subjects
with allergic rhinitis [173] and bacteria like Staphylococcus
aureus possess the ability to elicit exotoxins, and superan-
tigens can activate subpopulations of the T-lymphocytes
(5-30%) [174]. Bacterial superantigens in the patho-
genesis of CRSwNP, superantigen production, and host
T-lymphocyte response are crucial components of
common chronic eosinophilic-lymphocytic respiratory
mucosal disorders [175] and staphylococcal superantigen-
specific IgE antibodies to the superantigens SEA and SEB
have been detected in nasal polyp tissue [176].
In CRSwNP, there is an increase in the Th2 cytokines
like IL-4, IL-5 and IL-13 [177,178] and the intensity of
eosinophils in the tissues of these patients is markedly
increased in the presence of co-existing asthma or positive
allergy skin tests. The increased presence of IL-4 and
IL-13 can play a role in upregulating VCAM-1 and thus
facilitates the further infiltration by eosinophils. IL-4,
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upregulate eotaxin production in epithelial cells [178].
Immunoglobulins like IgA, IgE, IgG and IgM are also
increased in polyp fluid and tissue [177] and the con-
centrations of total IgE, IL-5, eotaxin, ECP, LTC4/D4/E4,
and sCD23 were significantly higher in nasal polyp tis-
sue as compared with non-polyp tissue [180]. Total IgE
correlates significantly with IL-5, ECP, LTC4/D4/E4, and
sCD23 and with the number of eosinophils in nasal
polyps [176,180]. In fact, IgE and IgA producing plasma
cells are particularly prominent within NP and the lo-
cally produced IgE and IgA are potentially involved in
activation of mast cells and eosinophils, which in turn
contribute to inflammation in these tissues [181]. Total
IgE levels in NPs are often highly increased, independent
of atopy. Specific IgE to SEs usually can be found locally
within the mucosa but not necessarily in the serum
[180-182]. Follicle-like structures can be identified fre-
quently in NP tissues, which highly express IgE anti-
bodies binding to SEs [184]. In addition to IgE, NPs
have increased IgA levels [182]. The observation of in-
creased local immunoglobulin production is supported
by the expression of the immunoglobulin diversification
enzyme activation-induced deaminase, indicating local im-
munoglobulin class-switching to IgE and IgA [170]. Local
IgE antibodies, although polyclonal and directed against a
range of inhalant and SE-related allergens, are functional
and capable of degranulating mast cells [184] and acti-
vated mast cells release histamine and tryptase which
upregulate the production of RANTES and GM-CSF
from epithelial cells thus facilitating eosinophil infiltra-
tion and survival [177,184-189]. In fact, increased levels
of tryptase and histamine (exceeding levels of 4000 ng/ml)
have been found in nasal polyps and a good correlation
between the levels of ECP and histamine and tryptase is
also documented [178-190]. Studies have shown local pro-
duction of IgE in the allergic nasal mucosa, and that mast
cells can drive this IgE production in B cells further en-
hancing the inflammation [191]. As mast cells can be
activated by polyclonal IgE; such a scenario can further
enhance the local inflammation. Furthermore, a deficiency
of Treg cells and increase in TSLP in nasal polyps (144)
may play an important role in the enhancement of the se-
verity of Th2 inflammation in nasal polyps and the persist-
ence and growth of NP [164,165]. More recently, Gevaert
et al demonstrated RAG1 and RAG2 mRNA concentra-
tions are increased in CRSwNP and correlated with the
magnitude of inflammation and the presence of S. aureus
enterotoxin (superantigen)-specific IgE in the nasal
polyp mucosa confirming local receptor revision and
class switching to IgE, and B-cell differentiation into
IgE-secreting plasma cells in CRSwNP [169].
The presence of SE-IgE antibodies and the increase in
local IgE suggests an association with the comorbidity ofasthma [162,192]. More recently, we (Kimura et al) have
demonstrated increased expression of Thymic Stromal
Lymphopoietin (TSLP) in nasal polyps irrespective of
the atopic status, as compared to the allergic nasal mu-
cosa and the TSLP expression was in good correlation
with eosinophils and IgE in the nasal polyp [144]. The
role of IgA in the pathology of CRS is unknown, but the
presence of IgA in patients with most types of chronic
mucosal inflammation, such as periodontitis, suggests
that IgA is important and might identify a unique endo-
type of CRS [193]
Recent findings point to superantigens as possible
causal agents in the intrinsic form of severe asthma, and
an anti-IgE strategy has shown promising therapeutic
potential in nonatopic patients with nasal polyps and
asthma [194]. These findings should lead to a clinically
relevant endotyping of patients with upper and lower
airway disease and to a new understanding of the role of
IgE 'above atopy'. A proof-of-concept study demonstrated
the functionality of local polyclonal IgE in the airways by
analyzing the effect of anti-IgE therapy in inducing a
substantial decrease in total polyp scores after 16 weeks in
the omalizumab group as compared with baseline values
by computed tomographic (CT) scanning. In addition,
Omalizumab significantly improved upper and lower
airway symptoms (nasal congestion, anterior rhinorrhea,
loss of sense of smell, wheezing, and dyspnea) and
asthma-related quality-of-life scores [195]. The demon-
stration of direct IgE switching and the existence of cellu-
lar IgE memory suggest the possibility of targeting these
mechanisms for the treatment of IgE-mediated diseases
[196,197]. A recent A PRACTALL document of the
European Academy of Allergy and Clinical Immunology
and the American Academy of Allergy, Asthma & Im-
munology has summarized the endotypes and phenotypes
of CRSwNP and CRSsNP [198] (Figure 2). More research
is required to clarify if CRS characterized by local IgE pro-
duction can be considered a CRS endotype.
Pathophysiology - infections, microbiome
Universal to the pathophysiology of chronic rhinosinusi-
tis (CRS) is the persistence of inflammation. The cause
of this inflammation in an individual patient, however, is
most often indiscernible [199]. An infectious etiology for
CRS has long been postulated [200]; although there is
significant scientific evidence that acute rhinosinusitis is
primarily an episodic viral infection of the paranasal si-
nuses, the scientific evidence for infection as a significant
component in the pathogenesis of CRS is less clear. Acute
exacerbations of CRS are likely due to infectious exacer-
bations secondary to viral infections. Although a causal
relationship has yet to be established between bacterial
infection and CRS, some studies [201,202] strongly impli-
cate bacterial infection. An interesting study examined the
Figure 2 Pathomechanisms of CRS. A. CRSwNP. In a TH2-type microenvironment with general lack of regulatory T (Treg) cell function, IL-5
induces eosinophilia, and IL-4 and IL-13 induce local IgE production. An alternatively activated macrophage subset contributes to the inflammation.
The activation of epithelium colonized by bacteria and fungi leads to release of proinflammatory chemokines and cytokines with increased thymic
stromal lymphopoietin (TSLP) and IL-32 levels. Activated epithelial cells die, with apoptosis resulting in a compromised epithelial barrier. B. CRSsNP.
Instead of a TH2-skewed T-cell response, a TH1 or a mixed TH0 response predominates, neutrophilia is often associated, and expression of TGF-β and
its receptors is increased. DC, Dendritic cell. This figure is reused with permission from the Journal of Allergy and Clinical Immunology [198].
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acute rhinosinusitis to CRS [201]. Patients in the study
had failed to respond to antibiotic treatment and had se-
quential cultures performed over a 5- to 7-week period
after the initial acute infection. Initially, typical bacteria for
acute rhinosinusitis were recovered, including Streptococ-
cus pneumoniae, Haemophilus influenzae, and Moraxellacatarrhalis. As patients transitioned to the chronic phase,
a mixed bacterial infection prevailed involving anaerobic
agents such as Prevotella, Fusobacterium, and Peptostrep-
tococcus species. This data provides evidence that bacteri-
ology in CRS is different from that of control patients
before acquisition of CRS. It is fair to say that bacteria are
encountered frequently in the setting of CRS; the flora of
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prevalence of Staphylococcus species and anaerobes. This
flora is often polymicrobial and may exhibit significant
antibiotic resistance. Also, a study which examined the
microbiology of recurrent infectious rhinosinusitis after
endoscopic sinus surgery has been reported [202]. The
data support bacterial infection as causing symptoms even
after endoscopic sinus surgery, further implying that bac-
teria even in patent sinuses may cause symptoms. There-
fore, it is highly likely that bacteria are involved at least to
some degree in the pathogenesis of CRS. The magnitude
of that involvement has yet to be determined [203].
Varying levels of involvement have been proposed, in-
cluding direct bacterial infection causing inflammation
and symptoms of CRS, bacterial by-products leading to
mucosal injury, and hypersensitivity to bacterial antigens
[203]. CRS can occur with or without nasal polyps, and
accumulating evidence now identifies Staphylococcus
aureus superantigens contributing to CRS with nasal
polyposis [181]. Superantigens are thought to affect mul-
tiple cell types and skew the cytokine response towards
a Th2 phenotype including both eosinophilia and the
production of polyclonal IgE, which in turn could be fur-
ther linked to asthma [162,204]. It remains unclear why
superantigen effects can be demonstrated in only approxi-
mately half of the cases of CRS with nasal polyposis;
hence, Staphylococcus aureus superantigens are generally
seen by many as disease modifiers rather than discrete
aetiologic agents [156].
Bacterial biofilms have also been implicated in CRS
aetiology and pathogenesis. Biofilms are highly organized
structures composed of communities of bacteria encased
within a protective extracellular matrix. The formation
of bacterial biofilms on surfaces such as the sinonasal
mucosa reflects a universal strategy for survival in condi-
tions less than optimal for growth [205,206]. Biofilms
serve to protect bacteria from both host defense and an-
tibiotics [207] and are believed to be a source of recur-
rent exacerbations in CRS through the periodic release
of free-floating planktonic bacteria [208]. Multiple stud-
ies have confirmed the presence of bacterial biofilms in
the sinonasal cavity of patients with CRS using operative
samples. Bacterial biofilms have been detected by various
methods in 30-100% of these samples [209]. Multiple
bacterial species have been associated with CRS biofilms
including Haemophilus influenzae, Staphylococcus aur-
eus, Streptococcus pneumoniae, Moraxella catarrhalis
[205,206,210-212]. In particular, Staphylococcus aureus
has been associated with a particularly poor prognosis
[213]. It has been suggested that Staphylococcus aureus
biofilm fosters a Th2 adaptive immune response inde-
pendent of any Staphylococcus aureus superantigen effect
[214]. Recent studies suggest that disruption of the host
epithelium may permit biofilm mediated inflammatoryeffects on the sinonasal tissues [215]. It is widely accepted
that biofilms are a bacterial adaptation facilitating re-
sistance to host defenses and antibiotics, helping to fos-
ter recalcitrant diseases. Moreover, it is also possible
that biofilm directed therapies will prove useful in the
management of CRS. However, it remains much less
clear whether biofilms have any role in the initial estab-
lishment of CRS [216].
Several recent studies have implicated fungi in the
pathogenesis of CRS. However, the role of fungi in CRS
has generated much controversy in the last decade
[217,218]. Sensitive detection techniques have shown the
presence of fungi in close to 100% of both CRS patients
and controls [219,220]. However, as opposed to controls,
eosinophils were exhibited in the nasal tissues and lumen
of CRS patients, with no evidence for IgE mediated mould
allergy according to serum data [219]. These observations
formed the basis of the “Fungal Hypothesis of CRS”, which
proposed that an excessive, non-IgE mediated host re-
sponse to common airborne fungi is the primary patho-
genic trigger in most form of CRS, both polypoid and
non-polypoid, varying only in intensity [221-223]. The
primary evidence cited to support this theory was the
relative hyper reactivity of peripheral blood mono-
nuclear cells (PBMC) from CRS patients in response to
stimulation with supra-physiologic doses of Alternaria
antigen in vitro [224]. Significantly higher levels of Th1
and Th2 were found in the PBMCs of CRS patients after
exposure to Alternaria extract, leading some to believe
that this heightened response reflected an immunologic
sensitization of T cells to Alternaria and therefore was
seen as a possible cause of the CRS inflammatory re-
sponse. As further evidence, nasal mucus or tissue from
CRS patients triggered eosinophil migration [225] and a
60-kDa component of the Alternaria fungus was later
shown to trigger eosinophil degranulation via PAR recep-
tor activation in vitro [226]. The effector role for eosino-
phils against fungi was proposed even though eosinophils
do not normally participate to a significant degree in the
host defense response targeting fungal organisms [227].
Further challenges to the “Fungal Hypothesis” included
the observation that the majority of patients in these stud-
ies [224,225] had concomitant asthma, and the heightened
cytokine responses from PBMCs as well as the eosinophil
migration may reflect priming by asthma rather than CRS
[217,218]. Also, other investigators failed to replicate the
fungal-induced cytokine responses from PBMCs, proving
there was clear universal hyper-responsiveness to fungal
antigens in CRS patients [228,229]. Despite these findings,
a series of drug trials using intranasal anti-fungal agents
was introduced that initially provided mixed support
[230-233]; finally, an extensive, multicenter, blinded, ran-
domized trial using intranasal amphotericin failed to show
any evidence of efficacy [234]. More significantly, a follow
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fect on any pro-inflammatory chemokine, cytokine or
growth factors in the CRS lavage samples [235]. Overall,
the current literature does not support the routine use
of topical anti-fungals for CRS [236] and there is little
support for the originally proposed fungal hypothesis.
Microbiome research is one of new perspectives in
human health research, including CRS. Studies on the
total genomes of bacteria inhabiting the body, termed
the microbiome, have recently been performed at National
Institutes of Health [237]. This Human Microbiome
Project (HMP) demonstrated the presence of more than
10,000 microbial species in the human body, and it was
estimated that 81-99% of the total microbial species
inhabiting healthy individuals were identified. The asso-
ciation between CRS and bacteria in the nasal cavity
and paranasal sinuses has been investigated in many
studies, but gene analysis of these bacteria to identify
the microbiome has only been performed in a few studies
[237-241]. The first reported study was performed in
2003, in which a bacteria-specific gene, 16 s rDNA, was
amplified from the mucosa and maxillary sinus lavage of
11 patients with maxillary sinusitis. Bacterial genes were
amplified in 4 patients and identified as Staphylococcus
aureus, gram-positives, -negatives, and anaerobes. How-
ever, no fungus was detected. In 2010, bacterial gene
analysis was performed using the mucosa. Bacterial
genes were amplified in all 18 patients, and Staphylococcus
aureus and coagulase - negative Staphylococci (CNS) was
detected in many samples along with anaerobes. The in-
volvement of anaerobes in the development of CRS has
been suggested, and this study demonstrated it at the gene
level. In another study, maxillary sinus lavage was ana-
lyzed, and a total of 142 bacterial genes were amplified in-
cluding many genes of indigenous bacteria in the oral
cavity. In a recently reported study, cotton swabs of 15
CRS patients were analyzed, and more than 50,000 bacter-
ial genes were detected in total. It was pointed out that
the incidence of asthma and the dominance of Staphylo-
coccus aureus increased as the diversity of bacterial genes
in the samples decreased. Questions remain with regard
to the relationship of CRS with the microbiome in the
nasal cavity and paranasal sinuses, also due to possible
contamination and inconsistency of the analytical methods.
Since the recent progression in analytical methods has
facilitated the investigation of the microbiome, further
studies of the relationship between CRS and the micro-
biome is warranted.
Clinical manifestation, diagnosis, and differential
diagnosis: adults
The diagnosis of chronic rhinosinusitis (CRS) is based
on the presence of two sinonasal symptoms in associ-
ation with clinical or radiological evidence for sinonasalinflammation. Two of the following symptoms should be
present: nasal secretions, nasal obstruction, facial pain,
or smell dysfunction. CRS has long been considered to
represent a heterogeneous collection of diseases.
Nasal polyposis is a subtype of chronic rhinosinusitis;
the term “polyp” refers to outgrowths of tissue into the
nasal cavity. The most common site of origin of nasal
polyps is the anterior ethmoid region. Nasal polyps cause
nasal obstruction, hyposmia, recurrent infection, and im-
paired quality of life. Twenty to 90% of patients with nasal
polyps have asthma. The large range reflexes both the se-
verity of the asthma, age of the patient and the presence of
aspirin sensitivity. When evaluating someone for nasal
polyps one should question about the presence of lung
disease.
Diagnosis
A negative physical examination can eliminate serious
diseases that mimic CRS.. Unilateral otitis media with
effusion can signal a mass in the nasopharynx. Facial
numbness raises concern about a sinus malignancy. Facial
swelling or interference with ocular movements portends
a complication of rhinosinusitis. Fever or enlarged neck
lymph nodes are not associated with routine CRS.
Whereas most sinusitis is rhinogenic in nature, dental
infections can initiate sinusitis. Purulent-appearing post
nasal discharge is a strong sign of a sinus infection.
The most common symptom is nasal obstruction.
Hypoxia, hypercapnia, snoring, sleep disorders, and an
increased risk of hypertension may develop in patients
with nasal polyposis. Polyps may obstruct airflow to the
olfactory cleft and lead to loss of the sense of smell
[242]. Nasal polyps are uncommon in children, and their
presence should prompt evaluation for cystic fibrosis. A
unilateral nasal polyp should raise the suspicion of an
inverted papilloma or tumor in adults, or of dermoid
cysts, encephaloceles, and gliomas in children. Examin-
ation of the oral cavity may show polyps behind the free
margin of the soft palate in cases of antrochoanal polyps
or postnasal drips that are related to coexisting sinusitis.
Nasal endoscopy provides excellent visualization of
polyps, especially of small polyps in the middle meatus. It
also shows nasal polyps originating from contact areas in
middle meatus and nasal anatomic abnormalities. Culture
of the discharge and a biopsy can be performed under
endoscopic guidance. Cultures from the middle meatus or
osteomeatal complex area have been shown to correlate
with cultures obtained from within the sinuses.
Computed tomography (CT) is the preferred technical
tool for confirming inflammation in the paranasal sinus
cavities. It shows the extent of disease. Caution should
be taken in the interpretation of the CT scan abnormal-
ities, as asymptomatic individuals may have CT scan ab-
normalities in the sinonasal cavities and a common cold
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itis may induce major inflammatory changes in all sinus
cavities. The timing of a CT scan and the correlation be-
tween symptoms and CT scan abnormalities are crucial
for a correct clinical diagnosis. A CT scan is essential in
cases of unilateral disease, suspect sinister pathology,
failure of medical treatment, and when complications
are suspected. CT is best performed after medical man-
agement for delineation of the chronic disease compo-
nent. CT is superior to magnetic resonance imaging
(MRI) in the depiction of bone details. MRI is advisable
when skull base erosion is noted adjacent to an area of
sinus opacity. It can differentiate between sinus disease
eroding the skull base and a meningocele or encephalo-
cele. MRI also helps to differentiate a tumor from secre-
tions retained secondary to obstruction by the tumor.
Other investigations include allergy testing, a pulmonary
function test, biopsies, a sweat chloride test, smell test or
genetic testing for detection of cystic fibrosis, aspirin in-
tolerance testing, swabs and fungal stains and cultures.
Skin testing does not always accurately confirm a role for
allergens in the absence of a definitive medical history or
positive nasal provocation test.
Differential diagnosis
The differential diagnosis can be divided into diseases
that mimic CRS and into diseases associated with CRS.
The differential diagnosis of CRS includes perennial and
persistent allergic rhinitis, nonallergic rhinitis, immotile
cilia syndrome, immunodeficiency, hormonal rhinitis, drug-
induced rhinitis, structural abnormalities, adenoidal hyper-
trophy, and tumors. Conditions associated with nasal
polyps include asthma, aspirin intolerance, allergic fungal
rhinosinusitis, Churg-Strauss syndrome, and cystic fi-
brosis. There is still an ongoing debate to as what is the
precise role of microorganisms in chronic rhinosinusitis.
Biofilms as well as mucosal immune responses to mi-
crobes may be involved in the pathology of CRS.
CRS maybe aggravated by anatomic deformities like
nasal septal deviations, septal perforations, and nasal valve
dysfunction. A clear nasal discharge may be a manifest-
ation of rhinitis, or of posttraumatic leakage of cere-
brospinal fluid, whereas colored secretions are often
encountered in the case of infectious exacerbations of
rhinosinusitis. Smell dysfunction, ranging from hypos-
mia to anosmia and parosmia, often represents a key
symptom of nasal polyps, but is also found in neurode-
generative diseases or intracranial lesions, or it may be
congenital. Facial pain or headache may have an odon-
togenic, vascular, or neurologic origin.
Besides the differential diagnosis, one should bear in
mind that rhinosinusitis represents a complex pathology,
with many factors influencing the severity of the disease.
Any underlying sensitization to inhalant allergens maygive rise to an allergic immune response that aggravates
the inflammation in CRS. Environmental factors, includ-
ing cigarette smoke, as well as occupational factors may
contribute to the disease process in CRS. These factors
should be taken into account when a patient with CRS is
evaluated, as diagnostic neglect of these conditions may
lead to suboptimal treatment [3,6,243-245].
Specific aspects in children
Pediatric rhinosinusitis is an important medical problem.
It is estimated that 5-10% of upper respiratory tract in-
fections (URI) in children are complicated by acute rhi-
nosinusitis (ARS) and 6-13% of all children develop
rhinosinusitis by the age of 3 years [246].
Of interest, the immunopathology of rhinosinusitis in
children may be distinct from adults. Chan et al. studied
the histopathology of young children (median age 3.0 years)
and revealed a predominant lymphocytic infiltration in-
stead of the typical eosinophilic infiltration found in adult
rhinosinusitis. They also demonstrated less submucosal
glandular hyperplasia and thinner epithelium and base-
ment membrane in pediatric compared to adult rhinosinu-
sitis [247]. These findings were confirmed in a recent
study which showed more epithelial shedding, tissue eo-
sinophilia and extensive fibrosis in CRS in adults than in
children [248]. It is unclear, however, whether this is just a
reflection of age or duration of disease, and disease pheno-
types are comparable.
Predisposing factors leading to rhinosinusitis in children
Adenoidal hypertrophy, URI and allergic rhinitis (AR)
are more common in children than in adults. A recent
study found that adenoids removed from children with
CRS had dense mature biofilms covering 95% of the mu-
cosal surface (versus 1.9% in controls) [249]. Of note,
chronic maxillary sinusitis and chronic otitis media with
effusion can occur concurrently in children and often
share the same organisms (in 69% of culture positive pa-
tients)[250]. In recurrent rhinosinusitis, the organisms
are likely to be resistant organisms [251]. Rhinosinusitis
caused by fungal infection is not common in children.
The underlying immunological defect should be searched
if such condition occurs [246].
Rhinosinusitis may also be a manifestation of gastro-
esophageal reflux (GERD). The acid reflux may cause
inflammation in the nasopharynx leading to mucosal
swelling and sinus ostial obstruction [252]. The treat-
ment of GERD by using histamine-2 receptor antagonist
and/or proton pump inhibitor may improve the symp-
toms of sinusitis in children [2].
Anatomical abnormalities are not common in children
[252-254]. Retention of secretion due to mucociliary
dysfunction can be found in immotile cilia syndrome
(Kartagener syndrome) and cystic fibrosis [252,253].
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with rhinosinusitis are B cell defects such as hypogam-
maglobulinemia, agammaglobulinemia, IgG subclass
deficiency, common variable immunodeficiency and
selective IgA deficiency. However, severe T-cell dys-
functions or immunosuppressive agents can lead to re-
current or severe rhinosinusitis. Furthermore, defects
of innate immunity such as collectin, antimicrobial
peptide or Toll-like receptor defects can facilitate rhi-
nosinusitis [252].
Clinical manifestation of rhinosinusitis in children
Children with rhinosinusitis can present with similar
symptoms as adults, but decreased sense of smell or
facial pain are less common while cough is more
common [6,253].
Investigations
CT scan of the sinuses is recommended in severe disease
or complications when surgical treatment might be indi-
cated [2,13]. Sinus aspiration and culture is recommended
in rare cases which do not respond to medical treatment,
immunodeficiency, severe disease with complications or
nosocomial infection [13,255].
Other investigations are considered to define predispos-
ing factors leading to CRS [2]. To exclude AR, skin prick
test should be done. If immunodeficiency is suspected,
measuring of IgG, IgA, IgM and IgG subclass as well as
assessing the specific antibody response to pneumococcal
vaccines are helpful. In immotile cilia syndrome, the
suggestive history includes frequent rhinosinusitis, otitis
media or pneumonia. Half of these patients have situs
inversus and/or dextrocardia. The saccharin test and bi-
opsy of inferior turbinate to examine the cilia under
electron microscope could confirm the diagnosis. In
cystic fibrosis, patients may present with a medialization
of the lateral nasal wall, nasal polyps, Pseudomonas aerugi-
nosa or Staphylococcus aureus infections in early child-
hood; the sweat chloride test is helpful, and genetic
investigations confirm the diagnosis [2].
Diagnosis
The European Rhinologic Society has developed a
European Position Paper on Rhinosinusitis and Nasal
Polyps (EPOS) in 2007 and updated in 2012 [6,13].
They suggested that the criteria for the diagnosis of
CRS in children included the following:
1. Symptoms persist for ≥ 12 wk with ≥ 2 symptoms,
one of which should be either nasal blockage/
obstruction/congestion or nasal discharge (anterior/
post nasal drip);
2. ± facial pain/pressure,
3. ± cough;In addition, allergy evaluation should be performed in
cases with suggestive history. CT scan is not recom-
mended unless surgery is considered.
Differential diagnosis
A foreign body in the nose should be suspected when
small children present with unilateral, foul-smell nasal
discharge. Adenoidal hypertrophy causes symptoms close
to CRS [2]. However, nasal congestion, snoring and hypo-
nasal voice are more common in adenoidal hypertrophy
than in CRS [13].
Complication
In young children, orbital complications in acute eth-
moiditis or maxillary sinusitis are more common than in
adults because of the thin bony walls between sinuses
and the orbit [13,246].
Management
The management scheme for CRS in children accord-
ing to our practice and to the EP3OS guideline is not
much different from adults, however adenoidectomy
and sinus irrigation should be considered before sur-
gery in case of young children. Ungkanont et al. re-
ported that adenoidectomy reduced rhinosinusitis
episodes especially in children with obstructive symp-
toms of the upper airway [256]. A meta-analysis sup-
ported that adenoidectomy decreased symptoms in
70% of CRS children [257].
Prevention in patients at high risk
1. Appropriate treatment of rhinosinusitis with
antibiotics according to the guidelines, if
unavoidable [258].
2. Decreased exposure to infection sources such as
avoid day care attendance, frequent hand washing
and avoid ill-contact [3].
3. Pneumococcal vaccine can decrease the incidence of
otitis media and pneumonia in children [259].
However, similar evidence for prevention of
rhinosinusitis is lacking.
4. Treatment of the underlying factors, if possible [258].
5. Antibiotic prophylaxis may be considered in CRS.
Wallwork et al. provided roxithromycin to adults
with CRS compared to placebo for 3 months and
found that the treatment group had less symptoms
of rhinosinusitis and increased mucociliary
function [260]. In children, we performed a
retrospective study using azithromycin for the
prevention of recurrent sinusitis and found a 50%
reduction of sinusitis episodes at 12 months of 70%
[261]. A prospective, randomized, double blinded,
placebo controlled study is ongoing.
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CRS is phenotyped as CRS without (CRSsNP) and with
nasal polyps (CRSwNP), based on symptoms (loss of
smell is typical for CRSwNP, headache and facial pain
are typical for CRSsNP) and nasal endoscopy (bilateral
presence of polyps in the nasal cavity) [1]. Knowledge
about the natural course of these diseases is currently
limited. It is unclear whether periods of acute rhinosinu-
sitis normally precede the onset of chronic sinus disease,
or a single episode is sufficient to initiate CRS, and how
the onset of disease differs from CRSsNP to CRSwNP. It
also is unknown which symptoms are the first to appear,
and the exact length of time until the disease is diag-
nosed and treated. So far, cigarette smoking is the only
identified risk factor for CRS [9]. However, there is a lack
of understanding of pathomechanisms and predictors for
disease recurrence, the impact of co-existing allergic dis-
ease, and the development of co-morbid asthma or aspirin
sensitivity. Furthermore the precise dynamics of levels of
inflammatory mediators in the natural course of disease,
in particular during acute exacerbation and exacerbation-
free interval as well as within the framework of the different
phenotypes and endotypes need to be better understood.
A recent Europe-wide epidemiologic study on the preva-
lence of CRS demonstrated a clear increased risk to suffer
from late-onset asthma for CRS patients [7]. Within CRS,
there is evidence that Th2-biased CRSwNP has a clearly
increased risk of asthma co-morbidity in Caucasians [162],
whereas CRSsNP does not significantly impact the de-
velopment of asthma, but is associated with other lower
airway disease [6]. The prominent predicting factor for
asthma co-morbidity in nasal polyps is IgE to staphylo-
coccal superantigens, SEs [162]; as there is recent evi-
dence that IgE to SEs is also associated with asthma
Europe-wide [262], and specifically has been linked to
severe late-onset asthma [263], it is likely that IgE to
SEs may play an important role in the expansion from
upper to lower airway disease.
Current initiatives to further differentiate CRS based
on endotypes (specific pathophysiological principles such
as Th2 driven inflammation) as well as the role of the
microbiome [264] will allow for better differentiating the
course of disease in the near future. This then will facili-
tate an estimation of the severity of disease and the socio-
economic burden to an individual and society.
Co-morbidities and contributing factors-asthma
and AERD
Asthma commonly co-exists with CRS [5]. Whether
chronic sinus disease causes asthma is debatable, it is
however clear that there is a strong link between the
two conditions. Connecting these conditions may be re-
lated to neural pathways, which can trigger the release
of inflammatory mediators; though less likely is the roleof micro-aspiration from the upper to the lower airways
[265]. Another possibility is a systemic immunologic
cross talk between the upper and lower airways [266].
There is evidence that markers such as interleukin-5 and
SE-IgE within the nasal polyp tissue are associated with
co-morbid asthma, supporting the idea of a systemic im-
munologic cross talk) [162]. Data from a 12 country
European study showed a strong association of asthma
with CRS (adjusted OR: 3.47; 95% CI: 3.20-3.76) at all
ages [7]. This survey also found that CRS in the absence
of nasal allergies was positively associated with late-onset
asthma.
Studies show a close relationship between the severity
of CRS and asthma. An Italian study found the frequency
of rhinosinusitis was the same in patients with mild-
moderate vs. severe corticosteroid-dependent asthma, but
sinus clinical symptomology and severity of sinus disease
documented by CT scan was significantly worse in the se-
vere corticosteroid-dependent asthmatics compared the
mild-moderate group [267]. A US study also found in-
creasing severity of asthma is associated with advancing
radiological severity of CRS [268]. Ten Brinke et al show a
direct connection between mucosal thickness in the si-
nuses and bronchial inflammation in severe asthma,
particularly in patients with adult-onset disease [269].
Also histopathological findings of asthma, including
epithelial shedding and basement membrane thickening
features of airway remodeling, eosinophillic infiltration,
T helper cell involvement and interleukin 5 production,
as well as IgE formation are present in CRS and asthma
[270,273], suggesting similar pathological processes in
CRS and asthma.
Aspirin-exacerbated respiratory disease (AERD) is a
clinical syndrome, which results in CRS with nasal polyps
and asthma and is exacerbated after ingestion of aspirin
(ASA) and non-steroidal anti-inflammatory drugs (NSAID)
[271]. This condition used to be called “aspirin triad” but
now is labeled AERD as the main underlying problem here
is a chronic inflammatory disease and not drug hypersen-
sitivity as it is only occasionally triggered by ASA or
NSAID. It tends to start in adulthood between 20 and
40 years of age. These aspirin sensitive asthmatics have a
much higher rate of nasal polyps compared to asthma
patients that are aspirin tolerant and have a much more
severe and protracted course with their CRS [272]. Clas-
sically nasosinal symptoms appear prior to asthma
followed by the development of nasal polyps. This entity
can be confirmed by ASA challenge testing. The path-
ology appears to be related to an imbalance between the
cyclooxygenase (COX) and lipoxygenase pathways leading
to overproduction of COX-1, which results in increased
production of cysteinyl leukotrienes. Also there is prob-
ably a role for cytokine production such as IL-5 and
staphylococcal superantigens amplifying the inflammatory
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quiring repeated surgeries related to the nasal polyposis
and aggressive asthma therapy with inhaled and/or oral
corticosteroids and other agents. Aspirin desensitization
may be beneficial in some of these patients.
Co-morbidities and contributing
factors – smoking, brochiectasis and COPD
Tobacco smoke exposure is considered an important
negative prognostic factor for chronic rhinosinusitis
(CRS), and smoking has been demonstrated to increase
the risk for CRS [9]. Tobacco smoke is composed of a
complex mixture of over 5000 substances [274] and
various chemicals in tobacco smoke have been identi-
fied as having high toxicity to respiratory cilia [275-277].
Additionally, tobacco smoke exposure has been shown to
increase pro-inflammatory cytokines such as TNF-α con-
tributing to harm respiratory mucosa [278,279]. There is
clear evidence in the literature that tobacco smoke, either
through active smoking or passive exposure to second-
hand smoke, contributes to CRS [280]. The prevalence of
CRS has been reported to be higher in smokers [281,282].
The impact of tobacco smoke exposure on endoscopic
sinus surgery (ESS) clinical outcomes has been investi-
gated and smokers have a less favorable response to ESS
[283,284]. It has been reported that both secondhand
smoke-sensitive and –nonsensitive individuals had in-
creased symptoms of rhinorrhea, nasal congestion, and
headache following sidestream smoke exposure [285]. In-
dividuals with known tobacco smoke sensitivity had more
severe symptoms than those without previous history of
secondhand smoke-related rhinitis. This study suggests
that certain people may be predisposed to the effects of to-
bacco smoke in terms of increased sinonasal physiological
and symptom response. Patients with sensitivity to to-
bacco smoke may be at higher risk for developing chronic
upper respiratory inflammation and disease, such as CRS
in response to secondhand smoke [280].
Studies have examined the pathophysiologic effects of
tobacco smoke on sinonasal mucosa in an effort to ex-
plain the biologic rationale for the clinical association of
smoke and CRS. The deleterious effects of cigarette
smoke relevant to CRS may include alterations in secre-
tion and ciliary beat frequency [286] as well as the in-
duction of bacterial biofilms [287]. Tobacco smoke has
also been demonstrated to have adverse effects on olfac-
tory mucosal metaplasia [288] and may adversely impact
olfaction [289,290]. Based on in vitro data, it has been
proposed that tobacco smoke in combination with viral
infection contributes to acute exacerbations and eo-
sinophilic inflammation in CRS patients [291]. Reactive
oxygen and reactive nitrogen species from tobacco
smoke induces pro-inflammatory cytokine secretion
[287], epithelial apoptosis [292,293] and diminishedairway epithelial barrier function [294]. The innate im-
mune function of sinonasal epithelium has become a
significant area of research as a potential cause of CRS.
These studies have shown alterations in locally expressed
pattern receptors such as Toll-like receptors (TLRs) and
innate immune effector proteins such as β-defensins and
complement components in CRS sinonasal epithelium
[295,296]. It has been reported that tobacco smoke has
immunosuppressive effects by suppressing monocyte-
derived macrophage function as well as by inhibiting
inflammatory cytokines through the suppression of the
TLR-mediated pathway in human bronchial epithelial
cells [297].
The suggestion we get from the overall data is that to-
bacco smoke is a likely contributor of inflammation in
CRS in exposed individuals, however there is little evi-
dence of the role of tobacco smoke as a causal agent of
CRS. In particular, it was suggested in a recent study
that in contrast to the lower airway, the upper airway
did not appear to be as affected by the pro-inflammatory
effects of tobacco smoke over time [298]. Outcome stud-
ies have also failed to show a strong negative effect from
smoking [299]. So far, there is little evidence to show
that tobacco smoke is a cause of CRS.
Epidemiologic and pathophysiologic studies demon-
strate that lower and upper airway diseases often coexist.
Chronic obstructive pulmonary disease (COPD) is a re-
spiratory disease, but also is a systemic disorder that
may be accompanied by weight loss, muscle weakness,
decreased functional capacity, anemia and osteoporosis.
The severity of the disease is defined by spirometric
measurements [300]. Tobacco smoke is the most im-
portant risk factor for COPD, and as mentioned above,
has a devastating potential for the nasal mucosa, and
may cause nasal symptoms [301], impairment of muco-
ciliary function [302], pathological signs of mucosal in-
flammation [303], and other changes [304]. Patients with
COPD remain less studied than those with asthma in
spite of the fact that a majority of COPD patients present
at an academic unit of respiratory disease experience sino-
nasal symptoms [305,306]. The frequency of sinonasal
symptoms such as nasal discharge, nasal obstruction, and
sneezing in COPD has been reported to be as high as 75 –
88% [305,307]. Recently, a high number of patients with
bronchiectasis have shown to be present with rhinosinusi-
tis symptoms, radiologic abnormalities on CT scans [308]
and have a reduced smell capacity [309]. Also, it has
been shown that COPD and CRS frequently coexist
[310]. Several pro-inflammatory mediators have been
found in nasal lavages of COPD patients [306] and nasal
symptoms corresponded with the overall impairment of
the quality of life [305]. Activation of nasal neutrophils
and capacity of producing secretory response to hista-
mine were found to be increased in cases with COPD
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alone. Nasal IL-8 was shown to be higher in COPD pa-
tients and this increase was correlated with the increase in
IL-8 level and bacterial load in sputum [303,311-314]. The
symptoms of CRS might be attributed to the systemic re-
flection of the inflammatory process in COPD. The con-
nection between COPD and CRS could result from the
simultaneous irritation of the lower and upper airways
by exhaling tobacco smoke through the nose. Such an
association could be demonstrated by the investigation
of inflammatory cells and markers and the examination
of tissue samples throughout the affected portions of
the respiratory mucosa [310]. Further study is needed to
disclose the immunopathologic mechanisms resulting




Intranasal corticosteroids (INS) are helpful in all types of
CRS. Their efficacy is supported by a high level of evi-
dence (1a recommendation) and, therefore, they are the
cornerstone of maintenance treatment [5]. Available data
support the use of beclomethasone dipropionate, bude-
sonide, flunisolide, fluticasone propionate, mometasone
furoate and tixocortol pivalate [244], although mostly
outside of the indication. Furthermore, the delivery sys-
tem appears to matter. Nasal drops and irrigation with
appropriate post application positioning appears to add
clinical benefit [315]. Long-term use of nasal drops and
irrigation has not been adequately studied and systemic
adverse effects, including increases of intraocular pressure,
require monitoring [10].
Systemic corticosteroids
Randomized double-blind, placebo controlled trials were
performed with prednisolone 50 mg daily for 14 days
[316] and methylprednisolone for 20 days [92] as a treat-
ment for CRSwNP. Improvements were seen in rhinosinu-
sitis outcome measure scores, extent of the disease on
magnetic resonance imaging scanning, reduction in polyp
size, and levels of eosinophil cationic protein (ECP), inter-
leukin 5 and IgE in nasal secretions.
Systemic antibiotics
Antibiotics are acknowledged as valuable for acute ex-
acerbations of CRS [3,2]. According to the Infectious
Diseases Society of America, amoxicillin-clavulanate is
recommended as empiric antimicrobial therapy for acute
bacterial rhinosinusitis in both adults and children [317].
However, in the absence of acute exacerbation, the use of
antibiotics for CRS is controversial because of lack of evi-
dence from well controlled clinical trials. The most appro-
priate patients with CRS for antibiotic treatment are thosewith persistent purulent drainage and documented infec-
tion with pathogenic organisms such as Staphylococcus
aureus, Pseudomonas aeruginosa or other pathogens.
These organisms can be associated with either acute or
chronic infection. Eradication of infection also requires
consideration of whether sinus aeration and adequate
mucociliary clearance can be restored.
Long-term systemic macrolide antibiotic treatment has
been advocated primarily as a treatment for CRSsNP [5].
In a study graded as level Ib evidence, in contrast to the
placebo group, patients in the roxithromycin group
showed a statistically significant change from baseline at
12 weeks in the SNOT-20 score, saccharine transit time
and nasal endoscopy findings [260]. Better responses
were seen in the subset of patients with a normal serum
IgE level [260]. In a study by Videler et al, 60 patients
with CRSsNP or CRSwNP were randomized to receive
azithromycin versus placebo 500 mg daily x 3 days, then
500 mg weekly for 11 weeks [318]. Multiple clinical as-
sessments were used, including symptom scoring, quality
of life assessment, rigid nasal endoscopy, peak nasal in-
spiratory flow and endoscopically-guided middle meatus
cultures. No significant differences were found between
groups at the end of treatment. It is possible that inclu-
sion of patients with elevated IgE levels or CRSwNP may
have contributed to the negative results of this study.
Regarding CRSwNP, doxycycline given over 20 days
also demonstrated efficacy compared to placebo in redu-
cing nasal polyp size [92].
Topical antibiotics
There is some evidence of efficacy for nasal irrigations
or nebulizations of antibiotics for CRS [319]. The highest
level of evidence derives from prospective observational
studies of post-surgical patients employing culture-
directed therapy [320]. Most studies involved nebulized
antibiotics for 3-6 weeks. Endoscopic improvement and
an increase in infection-free interval were reported. In
contrast, published placebo controlled trials failed to
show benefit but were quite limited in scope and num-
bers of patients.
Intranasal and systemic antifungals
Neither topical antifungal treatment (sprays and irriga-
tions) nor systemic terbinafine have been established
as beneficial for treatment of CRS. A double-blind,
placebo-controlled trial of topical amphotericin B in-
volving 24 patients treated for 6 months produced a
small but statistically significant improvement in sinus
mucosal thickening [231] without improvement in symp-
toms. However, a subsequent double blind, placebo-
controlled trial of 116 patients treated for 3 months
failed to show efficacy over placebo [234]. A 12-week
randomized controlled clinical trial of oral terbinafine
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in terms of symptomatic or radiographic improvement
for the treatment of CRS in 56 patients [321].
Antileukotrienes
These agents have been advocated as adjuncts to INS
for the treatment of CRSwNP. Modest benefit has been
noted after 1-3 months of montelukast or the 5-
lipoxygenase inhibitor zileuton in studies lacking pla-
cebo control [322,323]. However, placebo-controlled
studies have mostly failed to demonstrate benefit of
montelukast for nasal polyposis, and zileuton has not
been subjected to a placebo-controlled trial [5].
Adjunctive therapies
A Cochrane review of 8 studies using various forms of sa-
line sprays and irrigation performed 1-4 times daily found
that intranasal saline is an effective adjunctive treatment
for CRS [324]. Saline irrigation provides a subjective sense
of freshening, rinses away allergens and irritants, removes
secretions, improves mucociliary clearance, and reduces
postnasal drainage. An isotonic concentration is generally
preferred to hypertonic saline. Intranasal lavage (with at
least 200 ml of warmed saline per side) can be performed
with over-the-counter devices such as squeeze bottles, sy-
ringes and pots. Appropriate cleaning is required to avoid
contamination of the device.
The evidence does not currently support the use of
mucolytics, oral decongestants, or protracted adminis-
tration of intranasal decongestants for CRS. However,
therapies of associated conditions may aid the manage-
ment of CRS. These include antihistamines, environ-
mental control to reduce problematic exposures and
allergen immunotherapy for patients with allergic rhin-
itis, and H2 antagonists and proton pump inhibitors for
patients with laryngopharyngeal reflux. For patients with
aspirin-exacerbated respiratory disease (AERD), aspirin
desensitization followed by daily aspirin therapy has
been reported as beneficial for control of nasal polyps,
although placebo-controlled trials have not been con-
ducted [325-329].
CRS Pharmacotherapy
There is a relative paucity of controlled studies for this
indication. The design and interpretation of CRS clinical
trials has been hindered by the heterogeneity of the dis-
ease, a deficiency of uniform definitions for disease
subtypes, incomplete understanding of the underlying
pathologies, and a lack of useful and standardized clin-
ical and laboratory endpoints to measure response to
therapy. The most comprehensive treatment recom-
mendations for CRS are put forth in the EPOS consen-
sus document [5]. Recommendations are categorized
into 3 major subtypes: CRSsNP, CRSwNP and AFRS.Recommendations are also stratified according to disease
severity, using a visual analogue scale (VAS) of 0 (none) to
10 (most severe) [244].
CRSsNP (with evidence level)
1. Initially intranasal saline (A/Ib) and INS (A/Ib)
2. If after 3 months not improved, perform culture,
institute long-term macrolide therapy (A/Ib)
3. If improved, continue intranasal saline and INS
with/without macrolide therapy
4. If after the 3 months lack of response to this
strategy, consider CT scanning, surgery
Alternative recommendations to consider for initial
treatment: 10 day course of oral corticosteroids plus 3-4
week course of oral antibiotics (empirically selected or
guided by culture). Amoxicillin-clavulanate is an excellent
choice for most patients. Clindamycin or moxifloxacin are
useful for patients with penicillin allergy [10]. Macrolide
therapy may also be considered for initial treatment in
those with moderate/severe symptoms.
CRSwNP (with evidence level)
1. Initially INS (A/Ia) in double dosage, may be tapered
down if disease under control
2. If after 3 months not controlled, switch to INS
drops [1) (A/Ib), review after 3 months
3. Because of frequent mucosal colonization with S
aureus, doxycycline, 200 mg day 1, then 100 mg
for 20 days [92], initiate short course of oral
steroids (e.g., prednisolone 50 mg X14 days) [316]
(A/Ia)
4. If after 3 months not controlled, consider CT
scanning, surgery
Alternative recommendations to consider for initial
treatment:
1. Initially INS drops(A/Ib), a short course of oral
steroids (A/Ia) and doxycycline100mg/day for
3 weeks [92]
Additional recommendations to consider for mainten-
ance treatment: treatment of underlying allergic rhinitis,
aspirin desensitization followed by daily aspirin therapy
for post-surgical management of patients with AERD,
and antileukotriene agents [10].
AFRS (with evidence level)
1. Remove fungal mass and polyps (this usually
requires endoscopic sinus surgery)
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prednisolone started at 0.5 mg/kg daily with tapering
over a few weeks or longer, depending on control of
symptoms and mucosal disease) [10]. (Ia/A)
3. INS saline, INS and INS drops can be considered for
maintenance treatment as in CRSwNP [10]. (IV/D)
4. Intranasal or systemic antifungal agents have no
proven efficacy.
Additional recommendation to consider for initial
treatment: preoperative systemic corticosteroids may
help to improve sinus landmarks for surgery [10].
Surgical interventions
It is generally accepted that surgical intervention should
be considered when symptomatic chronic rhinosinusitis
(CRS) is refractory to appropriate medical therapy indicat-
ing that the sinus mucosal inflammation is not adequately
controlled [5]. The outcome (efficacy and safety) of sur-
gery at the individual level is influenced by two broad
categories of factors; patient-related factors such as the
phenotype of CRS, smoking or occupational exposure,
compliance to medication; and surgeon-related factors
such as the surgeon’s skills, the surgical techniques
employed, and postoperative management. While endo-
scopic sinus surgery (ESS) is widely considered as the
standard surgical intervention for CRS, the optimal
techniques for surgical treatment of CRS without nasal
polyps (CRSsNP) or CRS with nasal polyps (CRSwNP)
are still under debate.
Major advances in nasal endoscopy [330] and com-
puted tomography (CT) [331] over the last three decades
have resulted in the progress from sinus surgery prefer-
entially involving external approaches using a headlight
to surgery involving endoscopic intranasal approaches,
namely ESS [332]. Furthermore, advances in instrumen-
tation, such as through-cutting instrumentation, angled
suction irrigation drills, powered microdebriders, high-
quality three-chip or digital cameras, and interactive
computer-assisted frameless stereotactic surgical naviga-
tion systems have enabled the surgeon to perform pre-
cise and rapid dissections with mucosal preservation
under enhanced visualization [333].
Based on work of Messerklinger in 1978 [330], it is now
recognized that obstruction of the ostiomeatal complex
(OMC) is the critical etiologic factor in the pathogenesis
of CRSsNP and that mucosal damage was reversible [334].
The abbreviation FESS was first coined in 1985 by Ken-
nedy and colleagues [335], aimed at reversing the mucosal
inflammation and the mucociliary dysfunction of sinuses
by removing the diseased tissue from the target drainage
area of the OMC. However, “…simply draining involved
cells or sinuses may be insufficient in chronic disease”
[336,337]. Specifically in CRSwNP, persistent inflammationis likely to determine the long term outcome, and anti-
inflammatory strategies are mandatory.
Although it has been reported that the obstruction of
the sinus ostia initiates a cascade leading to rhinosinu-
sitis [338], the likelihood that improvements in sinus
ventilation alone are sufficient to cure the mucosal in-
flammation, especially in CRSwNP, is counterintuitive.
Surgical treatment should be considered as an adjunct
to the medical treatment of CRS rather than a stand-
alone procedure [339], at least for most of the patients,
if not for all. While a recent systemic review from the
Cochrane database indicated that the surgical proced-
ure did not confer an additional benefit to the treat-
ment of CRSsNP [340]; a more recent comparative
multi-centre study with 1-year follow-up has demon-
strated that ESS treatment led to significantly greater
QOL improvements than medical treatment in patients
with CRSsNP or CRSwNP who had previously failed to
improve with medical treatment [341].
In general, ESS is effective and safe for patients with
CRS resistant to medical treatment [342]. Dalziel and
colleagues [343] reviewed a total of 42 randomized con-
trolled trials, nonrandomized comparative studies, and
case series describing outcomes associated with FESS for
the excision of nasal polyps, and reported that FESS led
to symptomatic improvement in up to 98% of CRSwNP
patients with low frequency of major complications
(from 0 to 1.5%). Similarly, a systematic review of stud-
ies that investigated symptom severity scores to analyse
at least three major CRS criteria in adults recently dem-
onstrated that ESS led to symptomatic improvements in
both CRSsNP and CRSwNP [344]. A large prospective
study investigating long-term outcomes in a cohort of
1459 patients who had undergone surgery for CRS (with
or without nasal polyps) has recently demonstrated that
although sinonasal surgery was both safe and effective
in reducing the symptoms associated with CRS over a
5-year period, the overall revision surgery rate over
5 years was as high as 19.1%; with the revision surgery
rate for CRSwNP patients being higher than that for
CRSsNP patients (21% vs. 16%) [345]. It is noteworthy
that differences in the classification of CRS (CRSsNP or
CRSwNP), the instrument of evaluation (subjective or
objective), and the length of follow-up are all likely to
contribute to wide variations in the efficacy and safety
of ESS.
The extent of ESS and the techniques involved should
be tailored to the classification, phenotype, and severity
of the disease. Although we have not reached a con-
sensus on how to surgically resolve CRSw/sNP, the
techniques and technologies deployed in the surgical
treatment of CRS continue to evolve along with our
understanding of the pathophysiology of chronic sinus
inflammation.
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Two main innovative biological therapies have being in-
vestigated for efficacy and safety in adult patients with
chronic rhinosinusitis with nasal polyposis (CRSwNP):
omalizumab, a recombinant humanized monoclonal anti-
body against free immunoglobulin E (IgE), and reslizumab
and mepalizumab, two humanized antibodies against
interleukin (IL)-5.
Humanized monoclonal antibody against IgE
Omalizumab is approved for the treatment of severe aller-
gic asthma, otherwise failing to respond to asthma treat-
ment, with IgE serum levels between 30 and 1500 kU/L. It
has been demonstrated that total IgE levels are increased
in nasal secretions, polyp tissue, and serum of patients
with CRSwNP, comparable to findings in asthma [195]. In
fact, it is now clear that there is true local IgE formation in
nasal polyp tissue, which might be further triggered by
staphylococcal superantigens [169]. Two studies have pub-
lished case report series in patients being treated with
omalizumab for their comorbid severe asthma: in a pilot
study 4 treated patients showed a reduction in polyp size
but not in CT scores [346], and in a series of 19 (13 post-
operative) treated patients [347], all showed a reduction of
polyp size, use of intranasal corticosteroids, and further
sinonasal surgery. However, a negative underpowered
study also including CRSsNP patients has also been
published [348]. A recent randomized, double-blind,
placebo-controlled study with 24 patients with CRSwNP
and co-morbid asthma treated with omalizumab [196]Figure 3 "Pheno- and endotype" CRS. Pheno- and endotyping of CRS b
recurrence after surgery (Ghent classification of CRS).showed a significant reduction of polyp size, an im-
provement of bronchial and nasal symptoms, including
smell, quality of life, and sinus CT scan. The study sug-
gests that omalizumab does work in allergic and non/
allergic subjects. Patients with CRSwNP and comorbid
asthma, preferentially after sinonasal surgery, may ob-
tain a clear clinical benefit from omalizumab therapy
in both the lower and upper airways.
Humanized antibodies against IL-5
IL-5 is one of the most important eosinophil activating
factors orchestrating airway eosinophilic inflammation
[177]. The levels of IL-5 are elevated in nasal secretions,
polyp tissue, and serum of Caucasian patients with
CRSwNP. Two randomized, double blind, placebo-
controlled trials using anti-IL-5 antibodies, reslizumab
[349] and mepolizumab [350], have shown to reduce the
number of blood and tissue eosinophils and the size of
nasal polyps with a greater benefit for patients with high
levels of IL-5 in nasal secretions. Based on these studies,
the 2012 update of EPOS consensus [6] recommended
(grade A) the use of humanized antibodies against IL-5
for the treatment of patients with CRSwNP [351].
Unmet needs in chronic rhinosinusitis
Although it recently has been established that chronic rhi-
nosinusitis is a frequent disease in Europe and the US,
data from other continents are scarce, but are needed to
recognize differences and factors associated with CRS
prevalence. The tools to screen for CRS in epidemiological
studies need to be further developed, specifically in termsased on the recently published findings on asthma comorbidity and
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airway diseases such as allergic rhinitis. Factors predispos-
ing to CRS such as smoking need to be confirmed and
others identified, especially in childhood and adolescence.
We realize that CRS is an expensive disease with high
burden to the patient and the society; however, tools to
define disease severity and identify factors impacting on
pharmaco-economics are not well defined yet. The influ-
ence of disease subtype and patterns of inflammation
and co-morbidities on burden and costs need to be de-
fined, and treatment approaches need to be evaluated in
terms of appropriateness.
It has been established that co-morbid asthma is fre-
quent in CRS patients, however, the factors linking these
diseases specifically in late-onset non-atopic asthma are
only partially understood, and a better understanding of
the subgroups of CRS patients likely to develop asthma
[and disease recurrence) is necessary. This goes in paral-
lel with the need to “pheno- and endotype” CRS, most
likely involving tissue biomarkers and their surrogates in
serum and secretions (Figure 3). Again, these studies
need to be performed in various areas of the world, as
inflammation in CRS may considerably vary from region
to region, and also may show alterations over time.
Hypothesis-free approaches, based on –omics [genomics,
epigenomics, proteomics, metabolomics etc.), will ideally
lead to meaningful clusters of disease and offer new etio-
logical and pathophysiological pathways. However, this will
ask for a profound validation of those approaches for upper
airway disease, and a successful translation of specific
findings into clinical medicine. Once identified, those
clusters or endotypes will form the basis for further re-
search into genetics, environmental factors and micro-
biota, as they allow splitting up the umbrella term of
chronic rhinosinusitis.
At the same time, the natural course of disease and dis-
ease endotypes is far from clear, and factors impacting on
it, as the environment and pollution, the airway micro-
biome and exposure to antibiotics, and nutritional behavior,
need to be understood. We need to unravel the interactions
between the microbiota present in different forms and loca-
tions in the sinuses [planktonic, biofilms, intramucosal and
intracellular manifestations) and the type of inflammation,
building up on observations on the impact of Staphylococ-
cus aureus on the severity of CRS disease. The interaction
of the invaders with the innate and adaptive immune sys-
tem awaits clarification, from the immune proteome of
specific bacteria to the PAMPs and DAMPs of the airway
mucosa. Also, prior or due to the mucosal inflammation,
specific gaps in the mucosal defense are likely to play an
important role, including the immunity against bacteria
and viruses, and possibly also fungi.
With the endotyping of CRS, new diagnostic tools and
therapeutic interventions in carefully selected patientswill be possible, but need evaluation and positioning
within the management algorithm. Diagnosis of CRS will
not only rely on nasal endoscopy and CT scanning, but
include biomarkers. Furthermore, the current standards
including sinus surgery will be challenged, and most
probably changed especially in severely diseased pa-
tients with co-morbidity and disease recurrence. These
changes offer new perspectives for patients currently in-
adequately managed, but also challenges to our daily
practice.
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